Cheng-Hsun Ho1, Rong-Nan Chien2, Pin-Nan Cheng1, Jia-Huei Liu3, Cheng-Kun Liu2, Chih-Sheng Su2, I-Chin Wu1, I-Chen Li1, Hung-Wen Tsai4, Shiaw-Lin Wu5, Wen-Chun Liu1, Shu-Hui Chen6, Ting-Tsung Chang7. 1. Department of Internal Medicine. 2. Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Keelung, Taiwan. 3. Institute of Molecular Medicine, National Cheng Kung University Medical College. 4. Department of Pathology, National Cheng Kung University Hospital Infectious Disease and Signaling Research Center. 5. Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts. 6. Department of Chemistry, National Cheng Kung University, Tainan. 7. Department of Internal Medicine Institute of Molecular Medicine, National Cheng Kung University Medical College Infectious Disease and Signaling Research Center.
Abstract
BACKGROUND: Aberrant serum immunoglobulin G (IgG) glycosylation and its immunomodulatory effect are rarely addressed in chronic hepatitis B virus (HBV) infection. METHODS: Serum IgG-Fc glycosylation profiles in 76 patients with HBV-related liver cirrhosis and 115 patients with chronic hepatitis B (CHB) before and after 48 weeks of anti-HBV nucleos(t)ide analogue treatment were analyzed using high-throughput liquid chromatography-mass spectrometry and were compared to profiles in 108 healthy controls. RESULTS: The level of aberrant serum IgG-Fc glycosylation ,: particularly galactose deficiency, was higher in patients with CHB and those with cirrhosis (P < .001 for both) than in healthy controls. IgG galactose deficiency was correlated with the severity of liver necroinflammation and fibrosis in CHB. Multivariate logistic regression analyses showed that the IgG-Fc glycoform with fucosylation and fully galactosylation was an independent factor for a total Knodell necroinflammation score of ≥ 7 (odds ratio, 0.74; 95% confidence interval, .56-.97) and an Ishak fibrosis score of ≥ 3 (odds ratio, 0.69; 95% confidence interval, .49-.97). Administration of antiviral therapy for 48 weeks reversed aberrant IgG-Fc glycosylation in patients with CHB from week 12 onward but did not reverse glycosylation in patients with cirrhosis. Attenuated IgG opsonization in patients with CHB, which was correlated with aberrant Fc-glycosylation, was reversed after treatment as well. CONCLUSIONS: Aberrant serum IgG-Fc glycosylation in CHB, which is highly associated with histological liver damage, affects IgG opsonizing activity and can be reversed by antiviral therapy.
BACKGROUND: Aberrant serum immunoglobulin G (IgG) glycosylation and its immunomodulatory effect are rarely addressed in chronic hepatitis B virus (HBV) infection. METHODS: Serum IgG-Fc glycosylation profiles in 76 patients with HBV-related liver cirrhosis and 115 patients with chronic hepatitis B (CHB) before and after 48 weeks of anti-HBV nucleos(t)ide analogue treatment were analyzed using high-throughput liquid chromatography-mass spectrometry and were compared to profiles in 108 healthy controls. RESULTS: The level of aberrant serum IgG-Fc glycosylation ,: particularly galactose deficiency, was higher in patients with CHB and those with cirrhosis (P < .001 for both) than in healthy controls. IgG galactose deficiency was correlated with the severity of liver necroinflammation and fibrosis in CHB. Multivariate logistic regression analyses showed that the IgG-Fc glycoform with fucosylation and fully galactosylation was an independent factor for a total Knodell necroinflammation score of ≥ 7 (odds ratio, 0.74; 95% confidence interval, .56-.97) and an Ishak fibrosis score of ≥ 3 (odds ratio, 0.69; 95% confidence interval, .49-.97). Administration of antiviral therapy for 48 weeks reversed aberrant IgG-Fc glycosylation in patients with CHB from week 12 onward but did not reverse glycosylation in patients with cirrhosis. Attenuated IgG opsonization in patients with CHB, which was correlated with aberrant Fc-glycosylation, was reversed after treatment as well. CONCLUSIONS: Aberrant serum IgG-Fc glycosylation in CHB, which is highly associated with histological liver damage, affects IgG opsonizing activity and can be reversed by antiviral therapy.
Authors: Dieter Vanderschaeghe; Leander Meuris; Tom Raes; Hendrik Grootaert; Annelies Van Hecke; Xavier Verhelst; Frederique Van de Velde; Bruno Lapauw; Hans Van Vlierberghe; Nico Callewaert Journal: Mol Cell Proteomics Date: 2018-09-06 Impact factor: 5.911
Authors: Rosina Plomp; L Renee Ruhaak; Hae-Won Uh; Karli R Reiding; Maurice Selman; Jeanine J Houwing-Duistermaat; P Eline Slagboom; Marian Beekman; Manfred Wuhrer Journal: Sci Rep Date: 2017-09-26 Impact factor: 4.379
Authors: Patricia S Grace; Sepideh Dolatshahi; Lenette L Lu; Adam Cain; Fabrizio Palmieri; Linda Petrone; Sarah M Fortune; Tom H M Ottenhoff; Douglas A Lauffenburger; Delia Goletti; Simone A Joosten; Galit Alter Journal: Front Immunol Date: 2021-07-05 Impact factor: 7.561